2 research outputs found
Cystomanamides: Structure and Biosynthetic Pathway of a Family of Glycosylated Lipopeptides from Myxobacteria
Cystomanamides
A–D were isolated as novel natural product
scaffolds from <i>Cystobacter fuscus</i> MCy9118, and their
structures were established by spectroscopic techniques including
2D NMR, LC-SPE-NMR/-MS, and HR-MS. The cystomanamides contain β-hydroxy
amino acids along with 3-amino-9-methyldecanoic acid that is <i>N</i>-glycosylated in cystomanamide C and D. The gene cluster
for cystomanamide biosynthesis was identified by gene disruption as
PKS/NRPS hybrid incorporating an iso-fatty acid as starter unit and
including a reductive amination step at the interface of the PKS and
NRPS modules
Table1_Identification of dihydromyricetin as a natural DNA methylation inhibitor with rejuvenating activity in human skin.pdf
Changes in DNA methylation patterning have been reported to be a key hallmark of aged human skin. The altered DNA methylation patterns are correlated with deregulated gene expression and impaired tissue functionality, leading to the well-known skin aging phenotype. Searching for small molecules, which correct the aged methylation pattern therefore represents a novel and attractive strategy for the identification of anti-aging compounds. DNMT1 maintains epigenetic information by copying methylation patterns from the parental (methylated) strand to the newly synthesized strand after DNA replication. We hypothesized that a modest inhibition of this process promotes the restoration of the ground-state epigenetic pattern, thereby inducing rejuvenating effects. In this study, we screened a library of 1800 natural substances and 640 FDA-approved drugs and identified the well-known antioxidant and anti-inflammatory molecule dihydromyricetin (DHM) as an inhibitor of the DNA methyltransferase DNMT1. DHM is the active ingredient of several plants with medicinal use and showed robust inhibition of DNMT1 in biochemical assays. We also analyzed the effect of DHM in cultivated keratinocytes by array-based methylation profiling and observed a moderate, but significant global hypomethylation effect upon treatment. To further characterize DHM-induced methylation changes, we used published DNA methylation clocks and newly established age predictors to demonstrate that the DHM-induced methylation change is associated with a reduction in the biological age of the cells. Further studies also revealed re-activation of age-dependently hypermethylated and silenced genes in vivo and a reduction in age-dependent epidermal thinning in a 3-dimensional skin model. Our findings thus establish DHM as an epigenetic inhibitor with rejuvenating effects for aged human skin.</p